Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-04-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-2185PMID 23633452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

  2012cited by this paper
• The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction

  2012influential reference
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA*

  2011cited by this paper
• Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

  2011cited by this paper
• Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

  2011cited by this paper
• The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia

  2011cited by this paper
• Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

  2011influential reference
• Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

  2011cited by this paper
• Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL.

  2010cited by this paper
• Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

  2010influential reference
• Targeting the translational machinery as a novel treatment strategy for hematologic malignancies.

  2010cited by this paper
• 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

  2010cited by this paper
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

  2010cited by this paper
• Translational control in cancer

  2010cited by this paper
• Dysregulation of protein synthesis and disease

  2010cited by this paper
• Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

  2010cited by this paper
• ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

  2009cited by this paper
• Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.

  2009cited by this paper
• The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

  2009influential reference
• Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

  2009cited by this paper
• The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

  2009cited by this paper
• Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

  2009cited by this paper
• Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

  2008cited by this paper
• c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

  2008cited by this paper
• CD154 induces a switch in pro‐survival Bcl‐2 family members in chronic lymphocytic leukaemia

  2007cited by this paper
• Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

  2007cited by this paper
• Signal integration in the endoplasmic reticulum unfolded protein response

  2007cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.

  2007cited by this paper
• Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

  2007cited by this paper
• Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia

  2007cited by this paper
• Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita

  2006cited by this paper
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  2006cited by this paper
• A Selective Inhibitor of eIF2α Dephosphorylation Protects Cells from ER Stress

  2005cited by this paper
• A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress.

  2005cited by this paper
• Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

  2004cited by this paper
• The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

  2004cited by this paper
• CD40 stimulation of B‐cell chronic lymphocytic leukaemia cells enhances the anti‐apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T‐lymphocyte attack

  2004influential reference
• Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

  2004cited by this paper
• Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.

  2003cited by this paper
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas.

  1999cited by this paper
• Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.

  1996cited by this paper
• Ras mediates translation initiation factor 4E-induced malignant transformation.

  1992cited by this paper
• The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts

  1992cited by this paper
• Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.

  1992cited by this paper
• Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap

  1990cited by this paper
• A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

  1977cited by this paper

• eIF4F-mediated dysregulation of mRNA translation in cancer

  2025cites this paper
• Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy

  2025cites this paper
• Serum Interleukin 6 (IL -6) as Prognostic Marker in Egyptian CLL patients

  2024cites this paper
• Targeting mRNA translation in CLL.

  2023cites this paper
• Targeting mRNA translation aberrations: A novel approach for therapy in chronic lymphocytic leukemia

  2023cites this paper
• Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL

  2023cites this paper
• Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma

  2022cites this paper
• BAD regulates mammary gland morphogenesis by 4E-BP1-mediated control of localized translation in mouse and human models

  2021cites this paper
• Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role

  2020cites this paper
• Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms

  2020cites this paper
• The diversity, plasticity, and adaptability of cap-dependent translation initiation and the associated machinery

  2020cites this paper
• Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax

  2020cites this paper
• Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma

  2020cites this paper
• Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G.

  2019cites this paper
• Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers

  2019cites this paper
• CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

  2018cites this paper
• Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer

  2018cites this paper
• Advances in chronic lymphocytic leukemia pharmacotherapy.

  2018cites this paper
• A blood pact: the significance and implications of eIF4E on lymphocytic leukemia.

  2018cites this paper
• 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

  2018cites this paper
• Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation

  2018cites this paper
• Eukaryotic translation initiation factors and cancer

  2017cites this paper
• A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment

  2016cites this paper
• Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global RNA translation and translation of MYC RNA

  2016cites this paper
• Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

  2016cites this paper
• Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress

  2016cites this paper
• Targeting the translation machinery in cancer

  2015cites this paper
• RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia

  2015cites this paper
• The cap-translation inhibitor 4EGI-1 induces mitochondrial dysfunction via regulation of mitochondrial dynamic proteins in human glioma U251 cells.

  2015cites this paper
• Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

  2015cites this paper
• Hematological Malignancies and Premalignant Conditions

  2014cites this paper
• Current and Emerging Therapies Targeting Translation

  2014cites this paper
• Inhibidors de cinases com a estratègia terapèutica en neoplàsies limfoides

  2014cites this paper
• The structure of the complex between the translation initiation factor eIF 4 E with the inhibitor 4 EGI-1 reveals an allosteric mechanism for dissociating eIF 4

  2014cites this paper
• Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond

  2014cites this paper
• Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G

  2014cites this paper
• 4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis

  2014cites this paper
• Fingerprints of a message: integrating positional information on the transcriptome

  2014cites this paper